Bills · 2025-2026 Regular Session
Relating to: utilization management controls for antipsychotic prescription drugs under the Medical Assistance program. (FE)
Drugs Drunken driving Health services department of — Health Medical assistance Medical education United states — Food and drug administration
- Introduced, stopped here
- Passes Senate, not reached
- Passes Assembly, not reached
- Governor signs, not reached
- Law, not reached
Unfamiliar terms? Glossary
What this bill does
Plain-language analysis by the nonpartisan Legislative Reference Bureau
This bill prohibits the Department of Health Services from imposing any utilization management controls for prescription drugs under the Medical Assistance program that are approved by the federal Food and Drug Administration and are classified as antipsychotic. Utilization management controls are formal techniques used by a health carrier or prescription drug utilization management entity that are designed to evaluate prescription drug medical necessity, appropriateness, efficacy, or efficiency. Currently, DHS administers the Medical Assistance program, which is a joint federal and state program that provides health services to individuals who have limited financial resources.
What it would cost
Fiscal estimates filed by state agencies, as official PDFs
Sponsors
Registered lobbying interests · 13
Organizations that registered lobbying activity on this bill with the Wisconsin Ethics Commission. Registration means interest, not a position for or against. Official record
- Alliance of Health Insurers, U.A.
- CareSource Wisconsin
- Coalition of Wisconsin Aging Groups
- Elevance Health, and its affiliates dba Anthem Blue Cross Blue Shield
- Lundbeck Pharmaceuticals LLC
- Medical College of Wisconsin
- National Alliance on Mental Illness Wisconsin
- Otsuka America Pharmaceutical, Inc.
- Pharmacy Society of Wisconsin
- Wisconsin Academy of Family Physicians
- Wisconsin Association of Health Plans
- Wisconsin Nurses Association
- Wisconsin Psychiatric Association
Votes
Senate: Report adoption of Senate Substitute Amendment 2 recommended by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 3, Noes 2
Passed 3–2 Nov 12, 2025 official source full pageNo individual roll call was recorded for this vote. Committee votes and some older sessions record totals only.
Senate: Report passage as amended recommended by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 3, Noes 2
Passed 3–2 Nov 12, 2025 official source full pageNo individual roll call was recorded for this vote. Committee votes and some older sessions record totals only.
Full history
- Feb 26, 2025 · Senate
Introduced by Senators James, Cabral-Guevara and Wanggaard; cosponsored by Representatives Novak, Gundrum, B. Jacobson, Mursau, Sortwell, Steffen and Tittl
- Feb 26, 2025 · Senate
Read first time and referred to Committee on Mental Health, Substance Abuse Prevention, Children and Families
- Mar 27, 2025 · Senate
Fiscal estimate received
- May 16, 2025 · Senate
Senate Substitute Amendment 1 offered by Senator James
- Sep 9, 2025 · Senate
Representative Subeck added as a cosponsor
- Oct 3, 2025 · Senate
Senate Substitute Amendment 2 offered by Senator James
- Nov 6, 2025 · Senate
Public hearing held
- Nov 12, 2025 · Senate
Available for scheduling
- Nov 12, 2025 · Senate
Executive action taken
- Nov 12, 2025 · Senate
Report adoption of Senate Substitute Amendment 2 recommended by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 3, Noes 2
- Nov 12, 2025 · Senate
Report passage as amended recommended by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 3, Noes 2
- Mar 23, 2026 · Senate
Failed to pass pursuant to Senate Joint Resolution 1